Global Non-Hodgkin Lymphoma Treatment Market Research Report 2023
Non-Hodgkin’s lymphomas are one of the most commonly occurring cases of lymphomas and hence is also one of the most commonly occurring cancers. If not treated effectively, it is potentially lethal and leads to a shorter life span of the individuals diagnosed.
According to QYResearch’s new survey, global Non-Hodgkin Lymphoma Treatment market is projected to reach US$ 12810 million in 2029, increasing from US$ 7891 million in 2022, with the CAGR of 7.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Hodgkin Lymphoma Treatment market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-Hodgkin Lymphoma Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Non-Hodgkin Lymphoma Treatment market is projected to reach US$ 12810 million in 2029, increasing from US$ 7891 million in 2022, with the CAGR of 7.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Hodgkin Lymphoma Treatment market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-Hodgkin Lymphoma Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Bayer
- Novartis AG
- Gilead Sciences
- Spectrum Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Janssen Pharmaceuticals
- Roche
- CELGENE CORPORATION (Bristol Myers Squibb Company)
- Merck & Co., Inc.
- Kyowa Kirin Co., Ltd.
- AbbVie
- Sanofi
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immunotherapy
1.2.3 Targeted Therapy
1.2.4 Chemotherapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Non-Hodgkin Lymphoma Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Non-Hodgkin Lymphoma Treatment Market Perspective (2018-2029)
2.2 Non-Hodgkin Lymphoma Treatment Growth Trends by Region
2.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Non-Hodgkin Lymphoma Treatment Historic Market Size by Region (2018-2023)
2.2.3 Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Region (2024-2029)
2.3 Non-Hodgkin Lymphoma Treatment Market Dynamics
2.3.1 Non-Hodgkin Lymphoma Treatment Industry Trends
2.3.2 Non-Hodgkin Lymphoma Treatment Market Drivers
2.3.3 Non-Hodgkin Lymphoma Treatment Market Challenges
2.3.4 Non-Hodgkin Lymphoma Treatment Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue
3.1.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue (2018-2023)
3.1.2 Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Non-Hodgkin Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Hodgkin Lymphoma Treatment Revenue
3.4 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio
3.4.1 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Hodgkin Lymphoma Treatment Revenue in 2022
3.5 Non-Hodgkin Lymphoma Treatment Key Players Head office and Area Served
3.6 Key Players Non-Hodgkin Lymphoma Treatment Product Solution and Service
3.7 Date of Enter into Non-Hodgkin Lymphoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NON-HODGKIN LYMPHOMA TREATMENT BREAKDOWN DATA BY TYPE
4.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Type (2018-2023)
4.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2024-2029)
5 NON-HODGKIN LYMPHOMA TREATMENT BREAKDOWN DATA BY APPLICATION
5.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Application (2018-2023)
5.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
6.2 North America Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
6.4 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
7.2 Europe Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
7.4 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
8.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
9.2 Latin America Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
9.4 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
10.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Takeda Pharmaceutical Company Limited
11.1.1 Takeda Pharmaceutical Company Limited Company Detail
11.1.2 Takeda Pharmaceutical Company Limited Business Overview
11.1.3 Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Introduction
11.1.4 Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.1.5 Takeda Pharmaceutical Company Limited Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Non-Hodgkin Lymphoma Treatment Introduction
11.2.4 AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.2.5 AstraZeneca Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Non-Hodgkin Lymphoma Treatment Introduction
11.3.4 Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.3.5 Bayer Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Non-Hodgkin Lymphoma Treatment Introduction
11.4.4 Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.4.5 Novartis AG Recent Development
11.5 Gilead Sciences
11.5.1 Gilead Sciences Company Detail
11.5.2 Gilead Sciences Business Overview
11.5.3 Gilead Sciences Non-Hodgkin Lymphoma Treatment Introduction
11.5.4 Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.5.5 Gilead Sciences Recent Development
11.6 Spectrum Pharmaceuticals
11.6.1 Spectrum Pharmaceuticals Company Detail
11.6.2 Spectrum Pharmaceuticals Business Overview
11.6.3 Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
11.6.4 Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.6.5 Spectrum Pharmaceuticals Recent Development
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.7.3 Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Introduction
11.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.7.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.8 Bristol Myers Squibb Company
11.8.1 Bristol Myers Squibb Company Company Detail
11.8.2 Bristol Myers Squibb Company Business Overview
11.8.3 Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Introduction
11.8.4 Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.8.5 Bristol Myers Squibb Company Recent Development
11.9 Janssen Pharmaceuticals
11.9.1 Janssen Pharmaceuticals Company Detail
11.9.2 Janssen Pharmaceuticals Business Overview
11.9.3 Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
11.9.4 Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.9.5 Janssen Pharmaceuticals Recent Development
11.10 Roche
11.10.1 Roche Company Detail
11.10.2 Roche Business Overview
11.10.3 Roche Non-Hodgkin Lymphoma Treatment Introduction
11.10.4 Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.10.5 Roche Recent Development
11.11 CELGENE CORPORATION (Bristol Myers Squibb Company)
11.11.1 CELGENE CORPORATION (Bristol Myers Squibb Company) Company Detail
11.11.2 CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview
11.11.3 CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Introduction
11.11.4 CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.11.5 CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development
11.12 Merck & Co., Inc.
11.12.1 Merck & Co., Inc. Company Detail
11.12.2 Merck & Co., Inc. Business Overview
11.12.3 Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Introduction
11.12.4 Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.12.5 Merck & Co., Inc. Recent Development
11.13 Kyowa Kirin Co., Ltd.
11.13.1 Kyowa Kirin Co., Ltd. Company Detail
11.13.2 Kyowa Kirin Co., Ltd. Business Overview
11.13.3 Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Introduction
11.13.4 Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.13.5 Kyowa Kirin Co., Ltd. Recent Development
11.14 AbbVie
11.14.1 AbbVie Company Detail
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-Hodgkin Lymphoma Treatment Introduction
11.14.4 AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.14.5 AbbVie Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Non-Hodgkin Lymphoma Treatment Introduction
11.15.4 Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.15.5 Sanofi Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immunotherapy
1.2.3 Targeted Therapy
1.2.4 Chemotherapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Non-Hodgkin Lymphoma Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Non-Hodgkin Lymphoma Treatment Market Perspective (2018-2029)
2.2 Non-Hodgkin Lymphoma Treatment Growth Trends by Region
2.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Non-Hodgkin Lymphoma Treatment Historic Market Size by Region (2018-2023)
2.2.3 Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Region (2024-2029)
2.3 Non-Hodgkin Lymphoma Treatment Market Dynamics
2.3.1 Non-Hodgkin Lymphoma Treatment Industry Trends
2.3.2 Non-Hodgkin Lymphoma Treatment Market Drivers
2.3.3 Non-Hodgkin Lymphoma Treatment Market Challenges
2.3.4 Non-Hodgkin Lymphoma Treatment Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue
3.1.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue (2018-2023)
3.1.2 Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Non-Hodgkin Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Hodgkin Lymphoma Treatment Revenue
3.4 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio
3.4.1 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Hodgkin Lymphoma Treatment Revenue in 2022
3.5 Non-Hodgkin Lymphoma Treatment Key Players Head office and Area Served
3.6 Key Players Non-Hodgkin Lymphoma Treatment Product Solution and Service
3.7 Date of Enter into Non-Hodgkin Lymphoma Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NON-HODGKIN LYMPHOMA TREATMENT BREAKDOWN DATA BY TYPE
4.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Type (2018-2023)
4.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2024-2029)
5 NON-HODGKIN LYMPHOMA TREATMENT BREAKDOWN DATA BY APPLICATION
5.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Application (2018-2023)
5.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
6.2 North America Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
6.4 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
7.2 Europe Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
7.4 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
8.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
9.2 Latin America Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
9.4 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
10.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 Takeda Pharmaceutical Company Limited
11.1.1 Takeda Pharmaceutical Company Limited Company Detail
11.1.2 Takeda Pharmaceutical Company Limited Business Overview
11.1.3 Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Introduction
11.1.4 Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.1.5 Takeda Pharmaceutical Company Limited Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Non-Hodgkin Lymphoma Treatment Introduction
11.2.4 AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.2.5 AstraZeneca Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Non-Hodgkin Lymphoma Treatment Introduction
11.3.4 Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.3.5 Bayer Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Non-Hodgkin Lymphoma Treatment Introduction
11.4.4 Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.4.5 Novartis AG Recent Development
11.5 Gilead Sciences
11.5.1 Gilead Sciences Company Detail
11.5.2 Gilead Sciences Business Overview
11.5.3 Gilead Sciences Non-Hodgkin Lymphoma Treatment Introduction
11.5.4 Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.5.5 Gilead Sciences Recent Development
11.6 Spectrum Pharmaceuticals
11.6.1 Spectrum Pharmaceuticals Company Detail
11.6.2 Spectrum Pharmaceuticals Business Overview
11.6.3 Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
11.6.4 Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.6.5 Spectrum Pharmaceuticals Recent Development
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.7.3 Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Introduction
11.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.7.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.8 Bristol Myers Squibb Company
11.8.1 Bristol Myers Squibb Company Company Detail
11.8.2 Bristol Myers Squibb Company Business Overview
11.8.3 Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Introduction
11.8.4 Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.8.5 Bristol Myers Squibb Company Recent Development
11.9 Janssen Pharmaceuticals
11.9.1 Janssen Pharmaceuticals Company Detail
11.9.2 Janssen Pharmaceuticals Business Overview
11.9.3 Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
11.9.4 Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.9.5 Janssen Pharmaceuticals Recent Development
11.10 Roche
11.10.1 Roche Company Detail
11.10.2 Roche Business Overview
11.10.3 Roche Non-Hodgkin Lymphoma Treatment Introduction
11.10.4 Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.10.5 Roche Recent Development
11.11 CELGENE CORPORATION (Bristol Myers Squibb Company)
11.11.1 CELGENE CORPORATION (Bristol Myers Squibb Company) Company Detail
11.11.2 CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview
11.11.3 CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Introduction
11.11.4 CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.11.5 CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development
11.12 Merck & Co., Inc.
11.12.1 Merck & Co., Inc. Company Detail
11.12.2 Merck & Co., Inc. Business Overview
11.12.3 Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Introduction
11.12.4 Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.12.5 Merck & Co., Inc. Recent Development
11.13 Kyowa Kirin Co., Ltd.
11.13.1 Kyowa Kirin Co., Ltd. Company Detail
11.13.2 Kyowa Kirin Co., Ltd. Business Overview
11.13.3 Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Introduction
11.13.4 Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.13.5 Kyowa Kirin Co., Ltd. Recent Development
11.14 AbbVie
11.14.1 AbbVie Company Detail
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-Hodgkin Lymphoma Treatment Introduction
11.14.4 AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.14.5 AbbVie Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Non-Hodgkin Lymphoma Treatment Introduction
11.15.4 Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
11.15.5 Sanofi Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Immunotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Chemotherapy
Table 5. Key Players of Others
Table 6. Global Non-Hodgkin Lymphoma Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Non-Hodgkin Lymphoma Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Non-Hodgkin Lymphoma Treatment Market Share by Region (2018-2023)
Table 10. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Non-Hodgkin Lymphoma Treatment Market Share by Region (2024-2029)
Table 12. Non-Hodgkin Lymphoma Treatment Market Trends
Table 13. Non-Hodgkin Lymphoma Treatment Market Drivers
Table 14. Non-Hodgkin Lymphoma Treatment Market Challenges
Table 15. Non-Hodgkin Lymphoma Treatment Market Restraints
Table 16. Global Non-Hodgkin Lymphoma Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Players (2018-2023)
Table 18. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2022)
Table 19. Ranking of Global Top Non-Hodgkin Lymphoma Treatment Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Non-Hodgkin Lymphoma Treatment Product Solution and Service
Table 23. Date of Enter into Non-Hodgkin Lymphoma Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2018-2023)
Table 27. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2024-2029)
Table 29. Global Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2018-2023)
Table 31. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2024-2029)
Table 33. North America Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 48. Takeda Pharmaceutical Company Limited Company Detail
Table 49. Takeda Pharmaceutical Company Limited Business Overview
Table 50. Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Product
Table 51. Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 52. Takeda Pharmaceutical Company Limited Recent Development
Table 53. AstraZeneca Company Detail
Table 54. AstraZeneca Business Overview
Table 55. AstraZeneca Non-Hodgkin Lymphoma Treatment Product
Table 56. AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 57. AstraZeneca Recent Development
Table 58. Bayer Company Detail
Table 59. Bayer Business Overview
Table 60. Bayer Non-Hodgkin Lymphoma Treatment Product
Table 61. Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 62. Bayer Recent Development
Table 63. Novartis AG Company Detail
Table 64. Novartis AG Business Overview
Table 65. Novartis AG Non-Hodgkin Lymphoma Treatment Product
Table 66. Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 67. Novartis AG Recent Development
Table 68. Gilead Sciences Company Detail
Table 69. Gilead Sciences Business Overview
Table 70. Gilead Sciences Non-Hodgkin Lymphoma Treatment Product
Table 71. Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 72. Gilead Sciences Recent Development
Table 73. Spectrum Pharmaceuticals Company Detail
Table 74. Spectrum Pharmaceuticals Business Overview
Table 75. Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product
Table 76. Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 77. Spectrum Pharmaceuticals Recent Development
Table 78. Teva Pharmaceutical Industries Ltd. Company Detail
Table 79. Teva Pharmaceutical Industries Ltd. Business Overview
Table 80. Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Product
Table 81. Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 82. Teva Pharmaceutical Industries Ltd. Recent Development
Table 83. Bristol Myers Squibb Company Company Detail
Table 84. Bristol Myers Squibb Company Business Overview
Table 85. Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Product
Table 86. Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 87. Bristol Myers Squibb Company Recent Development
Table 88. Janssen Pharmaceuticals Company Detail
Table 89. Janssen Pharmaceuticals Business Overview
Table 90. Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product
Table 91. Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 92. Janssen Pharmaceuticals Recent Development
Table 93. Roche Company Detail
Table 94. Roche Business Overview
Table 95. Roche Non-Hodgkin Lymphoma Treatment Product
Table 96. Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 97. Roche Recent Development
Table 98. CELGENE CORPORATION (Bristol Myers Squibb Company) Company Detail
Table 99. CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview
Table 100. CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Product
Table 101. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 102. CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development
Table 103. Merck & Co., Inc. Company Detail
Table 104. Merck & Co., Inc. Business Overview
Table 105. Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Product
Table 106. Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 107. Merck & Co., Inc. Recent Development
Table 108. Kyowa Kirin Co., Ltd. Company Detail
Table 109. Kyowa Kirin Co., Ltd. Business Overview
Table 110. Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Product
Table 111. Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 112. Kyowa Kirin Co., Ltd. Recent Development
Table 113. AbbVie Company Detail
Table 114. AbbVie Business Overview
Table 115. AbbVie Non-Hodgkin Lymphoma Treatment Product
Table 116. AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 117. AbbVie Recent Development
Table 118. Sanofi Company Detail
Table 119. Sanofi Business Overview
Table 120. Sanofi Non-Hodgkin Lymphoma Treatment Product
Table 121. Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 122. Sanofi Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 1. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Immunotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Chemotherapy
Table 5. Key Players of Others
Table 6. Global Non-Hodgkin Lymphoma Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Non-Hodgkin Lymphoma Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Non-Hodgkin Lymphoma Treatment Market Share by Region (2018-2023)
Table 10. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Non-Hodgkin Lymphoma Treatment Market Share by Region (2024-2029)
Table 12. Non-Hodgkin Lymphoma Treatment Market Trends
Table 13. Non-Hodgkin Lymphoma Treatment Market Drivers
Table 14. Non-Hodgkin Lymphoma Treatment Market Challenges
Table 15. Non-Hodgkin Lymphoma Treatment Market Restraints
Table 16. Global Non-Hodgkin Lymphoma Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Players (2018-2023)
Table 18. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2022)
Table 19. Ranking of Global Top Non-Hodgkin Lymphoma Treatment Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Non-Hodgkin Lymphoma Treatment Product Solution and Service
Table 23. Date of Enter into Non-Hodgkin Lymphoma Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2018-2023)
Table 27. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2024-2029)
Table 29. Global Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2018-2023)
Table 31. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2024-2029)
Table 33. North America Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 48. Takeda Pharmaceutical Company Limited Company Detail
Table 49. Takeda Pharmaceutical Company Limited Business Overview
Table 50. Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Product
Table 51. Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 52. Takeda Pharmaceutical Company Limited Recent Development
Table 53. AstraZeneca Company Detail
Table 54. AstraZeneca Business Overview
Table 55. AstraZeneca Non-Hodgkin Lymphoma Treatment Product
Table 56. AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 57. AstraZeneca Recent Development
Table 58. Bayer Company Detail
Table 59. Bayer Business Overview
Table 60. Bayer Non-Hodgkin Lymphoma Treatment Product
Table 61. Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 62. Bayer Recent Development
Table 63. Novartis AG Company Detail
Table 64. Novartis AG Business Overview
Table 65. Novartis AG Non-Hodgkin Lymphoma Treatment Product
Table 66. Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 67. Novartis AG Recent Development
Table 68. Gilead Sciences Company Detail
Table 69. Gilead Sciences Business Overview
Table 70. Gilead Sciences Non-Hodgkin Lymphoma Treatment Product
Table 71. Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 72. Gilead Sciences Recent Development
Table 73. Spectrum Pharmaceuticals Company Detail
Table 74. Spectrum Pharmaceuticals Business Overview
Table 75. Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product
Table 76. Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 77. Spectrum Pharmaceuticals Recent Development
Table 78. Teva Pharmaceutical Industries Ltd. Company Detail
Table 79. Teva Pharmaceutical Industries Ltd. Business Overview
Table 80. Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Product
Table 81. Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 82. Teva Pharmaceutical Industries Ltd. Recent Development
Table 83. Bristol Myers Squibb Company Company Detail
Table 84. Bristol Myers Squibb Company Business Overview
Table 85. Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Product
Table 86. Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 87. Bristol Myers Squibb Company Recent Development
Table 88. Janssen Pharmaceuticals Company Detail
Table 89. Janssen Pharmaceuticals Business Overview
Table 90. Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product
Table 91. Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 92. Janssen Pharmaceuticals Recent Development
Table 93. Roche Company Detail
Table 94. Roche Business Overview
Table 95. Roche Non-Hodgkin Lymphoma Treatment Product
Table 96. Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 97. Roche Recent Development
Table 98. CELGENE CORPORATION (Bristol Myers Squibb Company) Company Detail
Table 99. CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview
Table 100. CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Product
Table 101. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 102. CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development
Table 103. Merck & Co., Inc. Company Detail
Table 104. Merck & Co., Inc. Business Overview
Table 105. Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Product
Table 106. Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 107. Merck & Co., Inc. Recent Development
Table 108. Kyowa Kirin Co., Ltd. Company Detail
Table 109. Kyowa Kirin Co., Ltd. Business Overview
Table 110. Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Product
Table 111. Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 112. Kyowa Kirin Co., Ltd. Recent Development
Table 113. AbbVie Company Detail
Table 114. AbbVie Business Overview
Table 115. AbbVie Non-Hodgkin Lymphoma Treatment Product
Table 116. AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 117. AbbVie Recent Development
Table 118. Sanofi Company Detail
Table 119. Sanofi Business Overview
Table 120. Sanofi Non-Hodgkin Lymphoma Treatment Product
Table 121. Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US$ Million)
Table 122. Sanofi Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Non-Hodgkin Lymphoma Treatment Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Non-Hodgkin Lymphoma Treatment Market Share by Type: 2022 VS 2029
Figure 3. Immunotherapy Features
Figure 4. Targeted Therapy Features
Figure 5. Chemotherapy Features
Figure 6. Others Features
Figure 7. Global Non-Hodgkin Lymphoma Treatment Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Non-Hodgkin Lymphoma Treatment Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Online Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Non-Hodgkin Lymphoma Treatment Report Years Considered
Figure 14. Global Non-Hodgkin Lymphoma Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Non-Hodgkin Lymphoma Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Non-Hodgkin Lymphoma Treatment Market Share by Region: 2022 VS 2029
Figure 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Players in 2022
Figure 18. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue in 2022
Figure 20. North America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 22. United States Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 26. Germany Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Share by Region (2018-2029)
Figure 34. China Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 42. Mexico Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 46. Turkey Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 49. AstraZeneca Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 50. Bayer Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 51. Novartis AG Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 52. Gilead Sciences Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 53. Spectrum Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 54. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 55. Bristol Myers Squibb Company Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 56. Janssen Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 57. Roche Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 58. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 59. Merck & Co., Inc. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 60. Kyowa Kirin Co., Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 61. AbbVie Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 62. Sanofi Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Figure 1. Global Non-Hodgkin Lymphoma Treatment Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Non-Hodgkin Lymphoma Treatment Market Share by Type: 2022 VS 2029
Figure 3. Immunotherapy Features
Figure 4. Targeted Therapy Features
Figure 5. Chemotherapy Features
Figure 6. Others Features
Figure 7. Global Non-Hodgkin Lymphoma Treatment Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Non-Hodgkin Lymphoma Treatment Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Online Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Non-Hodgkin Lymphoma Treatment Report Years Considered
Figure 14. Global Non-Hodgkin Lymphoma Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Non-Hodgkin Lymphoma Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Non-Hodgkin Lymphoma Treatment Market Share by Region: 2022 VS 2029
Figure 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Players in 2022
Figure 18. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue in 2022
Figure 20. North America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 22. United States Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 26. Germany Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Share by Region (2018-2029)
Figure 34. China Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 42. Mexico Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 46. Turkey Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 49. AstraZeneca Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 50. Bayer Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 51. Novartis AG Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 52. Gilead Sciences Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 53. Spectrum Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 54. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 55. Bristol Myers Squibb Company Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 56. Janssen Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 57. Roche Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 58. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 59. Merck & Co., Inc. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 60. Kyowa Kirin Co., Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 61. AbbVie Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 62. Sanofi Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
